Claims for Patent: 7,709,444

Summary for Patent: 7,709,444

Title:	Echinocandin pharmaceutical formulations containing micelle-forming surfactants
Abstract:	Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.
Inventor(s):	Milton; Nathaniel (Indianapolis, IN), Moder; Kenneth Philip (West Lafayette, IN), Sabatowski; James Lawrence (Holland, MI), Sweetana; Stephanie Ann (Bloomington, IN)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	11/103,798
Patent Claims:	1. A stabilized freeze-dried formulation comprising (i) an echinocandin compound, or a pharmaceutically acceptable salt thereof; (ii) a pharmaceutically acceptable micelle-forming surfactant with an HLB value of 10-18; (iii) a bulking agent; and (iv) a stabilizing agent, wherein said micelle-forming surfactant is present in said freeze-dried formulation in an amount greater than 5% by weight, and at a weight ratio of echinocandin compound to surfactant from about 1:1.75 to about 1:25; wherein said micelle-forming surfactant is not a block copolymer of propylene oxide and ethylene oxide; wherein, upon freeze drying, said freeze-dried formulation is a well-formed cake suitable for reconstitution as a parenteral pharmaceutical formulation suitable for intramuscular, intravenous or subcutaneous administration; wherein said echinocandin compound is represented by the following structure:, ##STR00010## wherein: R is a group having the structure: ##STR00011## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.6, R.sub.7, and R.sub.10 are hydroxy; R.sub.4 is methyl; R.sub.5 and R.sub.11 are methyl; R.sub.8 is --OH; R.sub.9 is --H; and pharmaceutically acceptable salts thereof; wherein said bulking agent is selected from the group consisting of mannitol, glycine, sucrose, trehalose, lactose, dextran, hydroxyethyl starch, ficoll and gelatin; and wherein said stabilizing agent is a carbohydrate. 2. The formulation of claim 1 wherein said micelle-forming surfactant is a polysorbate, a polyoxyethylene castor oil derivative, a polyoxyethylene stearate, or combinations thereof. 3. The formulation of claim 1 wherein said surfactant is a combination of micelle-forming surfactants with HLB values of 10-18. 4. The formulation of claim 3 wherein said weight ratio of echinocandin to surfactant is from about 1:2 to about 1:3. 5. The formulation of claim 1 further comprising a buffer. 6. The formulation of claim 5 where the buffer is selected from the group consisting of acetates, citrates, tartrates, lactates, succinates and phosphates and amino acids. 7. The formulation of claim 5 where the buffer is an acetate, citrate, or tartrate. 8. The formulation of claim 1 wherein the stabilizing agent is sucrose, fructose, trehalose or combinations thereof. 9. The formulation of claim 1 wherein the bulking agent is mannitol, sucrose, trehalose, lactose or combinations thereof. 10. The formulation of claim 1 wherein the stabilizing agent is fructose, or trehalose and the bulking agent is mannitol, lactose or combinations thereof. 11. The formulation of claim 7 wherein the stabilizing agent is fructose or trehalose and the bulking agent is mannitol, lactose or combinations thereof. 12. The formulation of claim 1 wherein said stabilizing agent is fructose, sucrose or trehalose, said bulking agent is mannitol or lactose, and said micelle forming surfactant is a polysorbate. 13. The formulation of claim 5 wherein said stabilizing agent is fructose, sucrose or trehalose, said bulking agent is mannitol or lactose, said micelle forming surfactant is a polysorbate, and said buffer is an acetate, citrate, or tartrate. 14. The formulation of claim 1 wherein said echinocandin compound is present prior to freeze drying at a concentration from 1 mg/ml to 30 mg/ml. 15. The formulation of claim 1 wherein said echinocandin compound is present prior to freeze drying at a concentration from 8 mg/ml to 12 mg/ml. 16. The formulation of claim 12 wherein said echinocandin compound is present prior to freeze drying at a concentration from 1 mg/ml to 30 mg/ml. 17. The formulation of claim 12 wherein said echinocandin compound is present prior to freeze drying at a concentration from 8 mg/ml to 12 mg/ml. 18. A parenteral formulation comprising the stabilized freeze-dried formulation of claim 1 and an aqueous solvent. 19. The formulation of claim 18 further comprising a buffer. 20. The formulation of claim 19 wherein said buffer is selected from the group consisting of acetates, citrates, tartrates, lactates, succinates, phosphates and amino acids. 21. The formulation of claim 20 where the buffer is an acetate, citrate, or tartrate. 22. A process for making the stabilized freeze-dried formulation according to claim 1 comprising in the following order the steps of: (i) dissolving into an aqueous solvent an echinocandin compound or echinocandin/carbohydrate complex containing said echinocandin compound in the presence of a pharmaceutically acceptable micelle-forming surfactant with an HLB value of 10-18 to form a solution, wherein said surfactant is present in an amount greater than 1% weight per volume of solution; (ii) sterile filtering said solution; and (iii) freeze-drying said solution; further comprising the step of adding one or more bulking agents and one or more stabilizing agents before step (ii) wherein said micelle-forming surfactant is not a block copolymer of propylene oxide and ethylene oxide; wherein said micelle-forming surfactant is present in said freeze-dried formulation in an amount greater than 5% by weight, and at a weight ratio of echinocandin to surfactant from 1:1.75 to 1:25; wherein the freeze dried formulation is a well-formed cake suitable for reconstitution as a parenteral pharmaceutical formulation suitable for intramuscular, intravenous or subcutaneous administration; wherein said bulking agent is selected from the group consisting of mannitol, glycine, sucrose, trehalose, lactose, dextran, hydroxyethyl starch, ficoll and gelatin; wherein said stabilizing agent is a carbohydrate; and wherein said echinocandin compound is represented by the following structure: ##STR00012## ##STR00013## wherein R is a group having the structure: ##STR00014## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.6, R.sub.7, and R.sub.10 are hydroxy; R.sub.4 is methyl; R.sub.5 and R.sub.11 are methyl; R.sub.8 is --OH; R.sub.9 is --H; and pharmaceutically acceptable salts thereof. 23. The process of claim 22 further comprising the step of adding one or more buffers, tonicity agents, combinations thereof before step (ii). 24. The process of claim 22 wherein said micelle-forming surfactant is a polysorbate, polyoxyethylene castor oil derivative, polyoxyethylene stearate, or combinations thereof. 25. The process of claim 22, wherein said micelle-forming surfactant is a combination of micelle-forming surfactants with HLB values of 10-18. 26. A process for preparing a stabilized freeze-dried formulation according to claim 1 comprising the steps of (i) buffering a non-toxic aqueous solvent to a pH between 4.0 and 5.5 to form a buffered solution; (ii) adding to said buffered solution a pharmaceutically acceptable, micelle-forming surfactant with an HLB value of 10-18; (iii) cooling the solution from step (ii) to a temperature between 5.degree. and 15.degree. C. to form a cooled solution; (iv) adding a slurry comprising an echinocandin compound or echinocandin/carbohydrate complex containing said echinocandin compound and a second non-toxic aqueous solvent to said cooled solution; (v) sterile filtering said solution from step (iv); and (vi) freeze-drying said solution from step (v); further comprising the step of adding one or more bulking agents and one or more stabilizing agents before step (v); wherein said micelle-forming surfactant is not a block copolymer of propylene oxide and ethylene oxide; wherein said micelle-forming surfactant is present in said freeze-dried formulation in an amount greater than 5% by weight, and at a weight ratio of echinocandin to surfactant from 1:1.75 to 1:25; and wherein the freeze dried formulation is a well-formed cake suitable for reconstitution as a parenteral pharmaceutical formulation suitable for intramuscular, intravenous or subcutaneous administration; wherein said bulking agent is selected from the group consisting of mannitol, glycine, sucrose, trehalose, lactose, dextran, hydroxyethyl starch, ficoll and gelatin: wherein said stabilizing agent is a carbohydrate; and wherein said echinocandin compound is represented by the following structure: ##STR00015## ##STR00016## wherein R is a group having the structure: ##STR00017## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.6, R.sub.7, and R.sub.10 are hydroxy; R.sub.4 is methyl; R.sub.5 and R.sub.11 are methyl; R.sub.8 is --OH; R.sub.9 is --H; and pharmaceutically accentable salts thereof; wherein said bulking agent is selected from the group consisting of mannitol, glycine, sucrose, trehalose, lactose, dextran, hydroxyethyl starch, ficoll and gelatin; and pharmaceutically acceptable salts thereof. 27. The process of claim 26 wherein said temperature in step (iii) is from about 7.degree. C. to about 10.degree. C. 28. A method of treating a fungal infection in a mammal in need thereof comprising the step of administering to said mammal a parenteral formulation of claim 18. 29. A method of treating a fungal infection in a mammal in need thereof comprising the step of administering to said mammal a parenteral formulation of claim 19.